Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21341404 | 0.76 | KDM4E (0.30) | CYP1A2KDM4ECYP3A4CYP2D6CYP2C19 | |
| SCHEMBL20618779 | 0.70 | KDM4E (0.39) | CFTRHTR2AHTR2CCNR2CYP1A2 | |
| SCHEMBL24944146 | 0.67 | — | — | |
| SCHEMBL12755272 | 0.63 | CDK4 (0.31) | — | |
| SCHEMBL11947342 | 0.61 | TAAR1 (0.52) | CYP1A2CYP2C19ALDH1A1 | |
| SCHEMBL10212114 | 0.59 | CA2 (0.39) | TDP1CYP1A2KDM4EALDH1A1POLB | |
| SCHEMBL11947321 | 0.59 | KCNH2 (0.50) | CYP1A2CYP2C19ALDH1A1 | |
| SCHEMBL21101086 | 0.57 | CNR2 (0.39) | HTR2AHTR2CCNR2CYP1A2KDM4E | |
| SCHEMBL22278010 | 0.57 | CA2 (0.38) | TDP1CYP1A2KDM4ECYP3A4CYP2D6 | |
| SCHEMBL21419317 | 0.57 | ALDH1A1 (0.55) | CNR2CYP1A2KDM4ECYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11130749-B2 | — | — | 2021-09-28 | — | — | US | disclosed |
| US-20190276440-A1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2019-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11130749-B2 | — | ROCK1, RHOA, ROCK2 | CFTR 777/4885HTR2A 4261/4885HTR2C 4621/4885 |
| US-20190276440-A1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF | ROCK1, ROCK2, RHOA | CFTR 1123/4885HTR2A 4416/4885HTR2C 4700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.